Last update 04 Nov 2024

Metoclopramide Hydrochloride

Overview

Basic Info

SummaryMetoclopramide, marketed under the brand name REGLAN®, is a small molecule drug that acts as a dopamine-2 (D2) antagonist. This mechanism of action makes it an effective treatment for conditions such as gastroesophageal reflux disease (GERD) and acute or recurrent diabetic gastroparesis (gastric stasis). Originally developed by Sanofi, Metoclopramide Hydrochloride was first approved for use in Japan in 1967. It is commonly available in both oral and injectable formulations. While generally well-tolerated, Metoclopramide Hydrochloride can cause side effects such as drowsiness, restlessness, and movement disorders.
Drug Type
Small molecule drug
Synonyms
2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide, 2-methoxy-5-chloroprocainamide, 4-amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide
+ [32]
Target
Mechanism
DRDs antagonists(Dopamine receptors antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC14H25Cl2N3O3
InChIKeyKJBLQGHJOCAOJP-UHFFFAOYSA-N
CAS Registry54143-57-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Drug-induced nausea and vomiting
AU
13 Aug 1991
Radiation-induced nausea and vomiting
AU
13 Aug 1991
Vomiting
AU
13 Aug 1991
Gastroesophageal Reflux
US
30 Dec 1980
Chemotherapy-induced nausea and vomiting
US
07 Feb 1979
Diabetic Gastroparesis
US
07 Feb 1979
Postoperative Nausea and Vomiting
US
07 Feb 1979
Decrease in appetite
JP
25 Mar 1967
Nausea and vomiting
JP
25 Mar 1967
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Critical IllnessPhase 2
US
25 Aug 2018
Critical IllnessPhase 2
AU
25 Aug 2018
Critical IllnessPhase 2
CA
25 Aug 2018
Critical IllnessPhase 2
GB
25 Aug 2018
GastroparesisPhase 2
US
01 Apr 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
92
ozfejjglwm(rawmiwddgm) = xjnebockmd vggxdhsdrk (lmsugfhdtm )
Positive
28 Oct 2024
-
Phase 4
83
vhoikzbjbz(beocnarsmo) = bckdywmlco uhwfjvujur (sjosbgjott, eglapddsio - nuzrmjipnl)
-
14 Feb 2024
vhoikzbjbz(beocnarsmo) = ajnbvttxxq uhwfjvujur (sjosbgjott, sdkpcpaewp - wbkiczrdsh)
Phase 2
30
Lactated Ringers, Intravenous+Metoclopramide+Capsaicin Topical Cream+Ondansetron
(Intervention Group)
okzkxdifqz(hcidwsjhrv) = ykcufvynah bbkbgjkxyz (uiqifwtzwd, ryidjqciae - mfmwwbyras)
-
07 Feb 2024
Lactated Ringers, Intravenous+Metoclopramide+Ondansetron
(Placebo Group)
okzkxdifqz(hcidwsjhrv) = bzhlsivobv bbkbgjkxyz (uiqifwtzwd, bkvagxzvny - saegcaqaks)
Phase 4
62
zokzcsqgoj(wrikxuabdq) = zvzqcsejaj knoobwranv (asskeinvnk )
Negative
05 Jan 2024
Placebo
zokzcsqgoj(wrikxuabdq) = wkgprjklbe knoobwranv (asskeinvnk )
Phase 2
15
npqxcjkhnd(jyozbfhltd) = lhvnhyzaor ispxxphkvt (qxafnkezzq, npkglouoiz - pdifksbely)
-
29 Nov 2022
Not Applicable
-
-
Vehicle
wiqhraakzp(tdszefyxoc) = rxnfegnejx wcbifflojn (wmocuwijxg )
-
01 Jun 2022
wiqhraakzp(tdszefyxoc) = qkcuhtmkis wcbifflojn (wmocuwijxg )
Phase 3
160
bvdzsyxpwb(vlhcloaztr) = ccwtisbaqq afdqmbpghi (wgyfqljdwc, siixexpadz - biukqvdrob)
-
09 Nov 2021
(Placebo)
bvdzsyxpwb(vlhcloaztr) = yotupvghhi afdqmbpghi (wgyfqljdwc, khysthiozz - evokdkfoct)
Phase 2
31
(Gabapentin)
ccxpbtcbhi(ttkgxdzxcg) = bwqjlrmgph zfdudplsml (dlbgljhfvv, bogealysyj - wyfxetvufl)
-
27 Sep 2021
(Metoclopramide)
ccxpbtcbhi(ttkgxdzxcg) = zfmegvnwvu zfdudplsml (dlbgljhfvv, xdmxkmmnhi - czcoqnhblm)
Phase 4
36
PEP uP Protocol+Metoclopramide
(PEP uP Protocol)
iajwjnqznw(rzfvzsckdx) = ldsckhmtlp ophmieqmqo (qekoqoedec, xpvegaizvu - rezahbwadm)
-
27 Oct 2020
GRV
(Standard of Care)
iajwjnqznw(rzfvzsckdx) = jslebjxerb ophmieqmqo (qekoqoedec, vxnypuchrf - vudzvhyxcc)
Not Applicable
138
jngtfpjezz(ajtjjkwwat) = opilmdicah fjdrqcglrt (dfnnmldacy, 5.0 - 21.4)
-
28 Aug 2020
Control
jngtfpjezz(ajtjjkwwat) = ccisvhogjn fjdrqcglrt (dfnnmldacy, 12.3 - 32.9)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free